Full-Time
Precision gene therapies for pediatric CNS.
No salary listed
Morrisville, NC, USA
In Person
Relocation assistance is not available. Travel up to 10% may be required.
Bachelor's
See people who can refer or advise you
Encoded Therapeutics develops precision gene therapies for pediatric central nervous system disorders, including Dravet syndrome. Its therapies use a unique targeting and regulation platform to deliver genetic payloads to specific brain cell types based on genetic profiles, increasing gene specificity, cell selectivity, and potency. The company aims to distinguish itself by focusing on cell-type–specific brain targeting and safety in pediatric patients to reduce off-target effects and toxicity compared with earlier gene therapies. Its goal is to bring clinically effective treatments to patients and work with healthcare providers to commercialize these therapies.
Company Size
51-200
Company Stage
Series F
Total Funding
$514.1M
Headquarters
San Francisco, California
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Parental Leave
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Health Savings Account/Flexible Spending Account
Stock Options
Encoded raises $275 million to push Dravet gene therapy into pivotal testing. 10 September 2026 US biotech company Encoded Therapeutics has closed a $275 million series F financing that will fund pivotal testing of ETX101, a gene therapy for Dravet syndrome, a severe form of childhood epilepsy. The privately held South San Francisco firm announced the round on Wednesday, days after presenting updated trial data at the European Epilepsy Congress. The financing was co-led by GV, the venture arm of Alphabet (Nasdaq: GOOGL), and a healthcare fund that was not named. Others taking part included ARCH Venture Partners, Braidwell, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors (NYSE: JHG), Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2 and Venrock. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 26 August 2026 7 September 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 10 September 2026 Company spotlight. A biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. More features in biotechnology. 10 September 2026
Encoded Therapeutics has closed a $275 million Series F financing round co-led by GV and another healthcare fund. The clinical-stage biotechnology company develops precision genetic medicines for severe neurological disorders. The proceeds will fund a pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, plus an expansion study for children and adolescents up to 18 years. The funding will also support commercial-scale GMP manufacturing and pipeline advancement, including ETX301 towards a 2027 Investigational New Drug submission for post-amputation neuroma pain. Participating investors include ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today highlights oral and poster presentations on the Company’s preclinical gene therapy programs and vector engineering platform at the 27th ASGCT Annual Meeting being held May 7 – 11, 2024 in Baltimore, MD.“ We are thrilled to share multiple advancements across our portfolio of precision genetic medicines, showcasing substantial progress across various fronts. These data underscore our platform’s potential to deliver precision therapies for a range of CNS diseases,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded. “ Alongside clinical advancement of our lead program, ETX101 for SCN1A+ Dravet syndrome, we are poised to nominate multiple programs to development in 2025, marking yet another significant milestone.”Oral PresentationTitle: GABA Selective AAV-mediated Gene Therapy Provides Durable Seizure Protection in Multiple Refractory Epilepsy Models (Abstract #19)Session: AAV Vectors - Preclinical and Proof-of-Concept: Therapy FocusDate & Time: Tuesday, May 7, 1:45–2:00 p.m. ETLocation: Ballroom 2Epilepsy affects approximately 1% of the population, with nearly one third of cases failing to respond to first- and second-line treatments. Encoded’s vector engineering platform has enabled the development of GABA-selective AAV-mediated gene therapies designed to potentiate GABAergic neurotransmission and modulate the circuit dysfunction underlying refractory epilepsies. Our lead candidate reduced seizure incidence and severity in two biologically distinct seizure assays with no adverse impact on body weight, motor function or locomotion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today announced the approval of its Clinical Trial Authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for the EXPEDITION Study of ETX101 as a potential treatment for children with SCN1A+ Dravet syndrome. Dravet syndrome is the most common developmental and epileptic encephalopathy and is characterized by a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation. The UK CTA for EXPEDITION is part of a global regulatory strategy established by Encoded for clinical development of ETX101, which also includes regulatory clearance for an investigational new drug (IND) application in the United States and approval under the Clinical Trial Approval (CTA) scheme in Australia. “This CTA marks the third regulatory approval for ETX101 as we advance our global clinical development program, POLARIS, to bring this potential one-time AAV gene regulation therapy to people affected by SCN1A+ Dravet syndrome around the world,” said Sal Rico, M.D., Ph.D., Chief Medical Officer of Encoded. “We believe ETX101 has the potential to deliver transformative benefit in multiple disease domains and have designed our clinical program to efficiently assess its impact on affected infants and young children. We are committed to working closely with our highly experienced investigators to expeditiously enroll affected children in an effort to advance therapeutic options for people living with Dravet syndrome.”
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today outlined the global development strategy for its lead gene therapy candidate, ETX101, for the treatment of SCN1A+ Dravet syndrome. Individuals with Dravet syndrome, the most common developmental and epileptic encephalopathy, experience a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation. Dravet syndrome is primarily caused by loss-of-function variants in the SCN1A gene, accounting for over 85% of cases. ETX101 is an AAV9-mediated candidate gene regulation therapy designed to selectively upregulate expression of the SCN1A gene in GABAergic inhibitory interneurons and potentially address the underlying cause of the disease. ETX101 Global Clinical Development. Encoded has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration and approval under the Clinical Trial Approval (CTA) scheme from the Australia Therapeutic Goods Administration to initiate clinical trials of its gene therapy candidate, ETX101